Therapeutic drug monitoring of osimertinib in non-small cell lung cancer and short bowel syndrome : A case report
© 2023 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society..
Short bowel syndrome (SBS) following extensive intestinal resection is often characterized by impaired absorption of orally administered drugs, including tyrosine kinase inhibitors (TKI). We report the case of a patient with EGFR-mutated non-small cell lung carcinoma treated with 80 mg/day of the TKI osimertinib who achieved partial response of the tumour, but was subsequently subjected to a double-barrelled jejunostomy due to ileus. Due to the development of SBS after the bypass surgery, plasma concentrations of osimertinib were monitored using mass spectrometry. The therapeutic drug monitoring confirmed a malabsorption of osimertinib in the patient (108 ng/mL, which is below the 5th percentile of the expected plasma concentration) and was useful to guide adjustments of TKI dosing in order to achieve adequate blood levels (161 ng/mL after increase of the dose to 120 mg/day) in order to maintain tumour control.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:90 |
|---|---|
| Enthalten in: |
British journal of clinical pharmacology - 90(2024), 1 vom: 21. Jan., Seite 344-349 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Longuespée, Rémi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
3C06JJ0Z2O |
|---|
| Anmerkungen: |
Date Completed 29.12.2023 Date Revised 05.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/bcp.15924 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363084517 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363084517 | ||
| 003 | DE-627 | ||
| 005 | 20240305232001.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bcp.15924 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1317.xml |
| 035 | |a (DE-627)NLM363084517 | ||
| 035 | |a (NLM)37815301 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Longuespée, Rémi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Therapeutic drug monitoring of osimertinib in non-small cell lung cancer and short bowel syndrome |b A case report |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.12.2023 | ||
| 500 | |a Date Revised 05.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. | ||
| 520 | |a Short bowel syndrome (SBS) following extensive intestinal resection is often characterized by impaired absorption of orally administered drugs, including tyrosine kinase inhibitors (TKI). We report the case of a patient with EGFR-mutated non-small cell lung carcinoma treated with 80 mg/day of the TKI osimertinib who achieved partial response of the tumour, but was subsequently subjected to a double-barrelled jejunostomy due to ileus. Due to the development of SBS after the bypass surgery, plasma concentrations of osimertinib were monitored using mass spectrometry. The therapeutic drug monitoring confirmed a malabsorption of osimertinib in the patient (108 ng/mL, which is below the 5th percentile of the expected plasma concentration) and was useful to guide adjustments of TKI dosing in order to achieve adequate blood levels (161 ng/mL after increase of the dose to 120 mg/day) in order to maintain tumour control | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a LC-MS/MS | |
| 650 | 4 | |a MALDI-MS/MS | |
| 650 | 4 | |a non-small cell lung cancer | |
| 650 | 4 | |a osimertinib | |
| 650 | 4 | |a short bowel syndrome | |
| 650 | 4 | |a therapeutic drug monitoring | |
| 650 | 7 | |a osimertinib |2 NLM | |
| 650 | 7 | |a 3C06JJ0Z2O |2 NLM | |
| 650 | 7 | |a ErbB Receptors |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
| 700 | 1 | |a Kunz, Julia |e verfasserin |4 aut | |
| 700 | 1 | |a Fresnais, Margaux |e verfasserin |4 aut | |
| 700 | 1 | |a Foerster, Kathrin I |e verfasserin |4 aut | |
| 700 | 1 | |a Burhenne, Jürgen |e verfasserin |4 aut | |
| 700 | 1 | |a Thomas, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Kazdal, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Stenzinger, Albrecht |e verfasserin |4 aut | |
| 700 | 1 | |a Christopoulos, Petros |e verfasserin |4 aut | |
| 700 | 1 | |a Haefeli, Walter E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of clinical pharmacology |d 1974 |g 90(2024), 1 vom: 21. Jan., Seite 344-349 |w (DE-627)NLM000097799 |x 1365-2125 |7 nnns |
| 773 | 1 | 8 | |g volume:90 |g year:2024 |g number:1 |g day:21 |g month:01 |g pages:344-349 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/bcp.15924 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 90 |j 2024 |e 1 |b 21 |c 01 |h 344-349 | ||